Mark S. Knapp

3.6k citations

38 papers · 3.0k · 1 hit paper · h-index 21

Impact in

Genetics top 5%
- Chronic Lymphocytic Leukemia Research
Molecular Biology top 5%
- PI3K/AKT/mTOR signaling in cancer
- Protein Degradation and Inhibitors
- Ubiquitin and proteasome pathways
- Biochemical and Molecular Research

Papers in

Molecular Biology 24
- PI3K/AKT/mTOR signaling in cancer 10
- Biochemical and Molecular Research 4
- Protein Kinase Regulation and GTPase Signaling 3
- Cancer therapeutics and mechanisms 3
Genetics 4
- Chronic Lymphocytic Leukemia Research 4

Co-authors: Bernhard Rupp (5 shared papers)Karl Heinrich Weisgraber (1 shared paper)Mark L. Segall (1 shared paper)Sissel Lund‐Katz (1 shared paper)Michael C. Phillips (1 shared paper)Julie A. Morrow (1 shared paper)Pascal Furet (4 shared papers)Joachim Blanz (3 shared papers)
Journals: ACS Medicinal Chemistry Letters (6 papers)Bioorganic & Medicinal Chemistry Letters (5 papers)Journal of Medicinal Chemistry (5 papers)Biochemistry (2 papers)Proceedings of the National Academy of Sciences (2 papers)
Partner nations: United States Switzerland China

In The Last Decade

Mark S. Knapp

36 papers receiving 2.9k citations

Mark S. Knapp's Hit Papers

align trajectories log scale

Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo 2014 · 670 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2014 Nature Cell Biology

Peers

Countries citing papers authored by Mark S. Knapp

Since Specialization

Citations

This map shows the geographic impact of Mark S. Knapp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark S. Knapp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark S. Knapp more than expected).

Fields of papers citing papers by Mark S. Knapp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark S. Knapp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark S. Knapp. The network helps show where Mark S. Knapp may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark S. Knapp, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark S. Knapp Line = papers co-authored together Mark S. Knapp links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo Nature Cell Biology ·William E. Dowdle, Beat Nyfeler, Jane Nagel, Robert A. Elling, Shanming Liu, Ellen Triantafellow, Suchithra Menon, Zuncai Wang Hit paper breakdown →	2014	670
2	Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor Molecular Cancer Therapeutics ·Sauveur-Michel Maira, Sabina Pecchi, Alan Huang, Matthew T. Burger, Mark S. Knapp, Dario Sterker, Christian Schnell, Daniel Alexander Guthy	2011	475
3	Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation Bioorganic & Medicinal Chemistry Letters ·Pascal Furet, Vito Guagnano, Robin A. Fairhurst, Patricia Imbach‐Weese, Ian C. Bruce, Mark S. Knapp, Christine M. Fritsch, Francesca Blasco	2013	394
4	Differences in Stability among the Human Apolipoprotein E Isoforms Determined by the Amino-Terminal Domain Biochemistry ·Julie A. Morrow, Mark L. Segall, Sissel Lund‐Katz, Michael C. Phillips, Mark S. Knapp, Bernhard Rupp, Karl Heinrich Weisgraber	2000	277
5	Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer ACS Medicinal Chemistry Letters ·Matthew T. Burger, Sabina Pecchi, Allan S. Wagman, Zhi‐Jie Ni, Mark S. Knapp, Thomas F. Hendrickson, Gordana Atallah, Keith B. Pfister	2011	222
6	Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex Nature Chemical Biology ·Dirksen E. Bussiere, Lili Xie, Honnappa Srinivas, Wei Shu, Ashley A. Burke, Celine Be, Junping Zhao, Adarsh Godbole	2019	197
7	Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance Nature Communications ·Ala M. Shaqra, Sarah N. Zvornicanin, Qiu Yu J. Huang, G.J. Lockbaum, Mark S. Knapp, Laura Tandeske, David T. Bakan, Julia M. Flynn	2022	95
8	Crystal structure of Clostridium botulinum neurotoxin protease in a product-bound state: Evidence for noncanonical zinc protease activity Proceedings of the National Academy of Sciences ·Brent W. Segelke, Mark S. Knapp, Saloumeh Kadkhodayan, Rod Balhorn, Bernhard Rupp	2004	86
9	Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors ACS Medicinal Chemistry Letters ·Klemens Hoegenauer, Nicolas Soldermann, Frédéric Stauffer, Pascal Furet, Nadège Graveleau, Alexander B. Smith, Christina Hebach, Gregory J. Hollingworth	2016	55
10	Potent, Selective, and Orally Bioavailable Inhibitors of VPS34 Provide Chemical Tools to Modulate Autophagy in Vivo ACS Medicinal Chemistry Letters ·Ayako Honda, Edmund M. Harrington, Iván Cornella‐Taracido, Pascal Furet, Mark S. Knapp, Meir Glick, Ellen Triantafellow, William E. Dowdle	2015	49
11	Structure-guided enzymology of the lipid A acyltransferase LpxM reveals a dual activity mechanism Proceedings of the National Academy of Sciences ·Dustin Dovala, Christopher M. Baxter Rath, Qijun Hu, William S. Sawyer, Steven Shia, Robert A. Elling, Mark S. Knapp, Louis Eugene Metzger	2016	40
12	Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR Inhibitors Journal of Molecular Biology ·Yipin Lu, Mark S. Knapp, Kenneth R. Crawford, Robert L. Warne, Robert A. Elling, Kelly Yan, MICHAEL V. DOYLE, Gwynn Pardee	2017	35
13	Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR Inhibitors ACS Medicinal Chemistry Letters ·Paul A. Barsanti, Robert J. Aversa, Xianming Jin, Yue Pan, Yipin Lu, Robert A. Elling, Rama Jain, Mark S. Knapp	2014	35
14	Identification and structure–activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Sabina Pecchi, Paul A. Renhowe, Clarke B. Taylor, Susan Kaufman, Hanne Merritt, Marion Wiesmann, Kevin R. Shoemaker, Mark S. Knapp	2010	29
15	Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors ACS Medicinal Chemistry Letters ·Matthew T. Burger, Mark S. Knapp, Allan S. Wagman, Zhi‐Jie Ni, Thomas F. Hendrickson, Gordana Atallah, Yanchen Zhang, Kelly A. Frazier	2010	29
16	Potent Nonimmunosuppressive Cyclophilin Inhibitors With Improved Pharmaceutical Properties and Decreased Transporter Inhibition Journal of Medicinal Chemistry ·Jiping Fu, Meiliana Tjandra, Christopher J. Becker, Dallas Bednarczyk, Michael P. Capparelli, Robert A. Elling, Imad H. Hanna, Roger A. Fujimoto	2014	28
17	Identification of Novel Small Molecule Ligands That Bind to Tetanus Toxin Chemical Research in Toxicology ·Felice C. Lightstone, Maria Consuelo Hart Prieto, Anup Kumar Singh, Mari Carmen Piqueras, Randy M. Whittal, Mark S. Knapp, Rod Balhorn, Diana C. Roe	2000	27
18	Carboxyl-Terminal Domain of Human Apolipoprotein E: Expression, Purification, and Crystallization Protein Expression and Purification ·Michael Forstner, Clare A. Peters-Libeu, Emeline Contreras-Forrest, Yvonne M. Newhouse, Mark S. Knapp, Bernhard Rupp, Karl H. Weisgraber	1999	25
19	Cloning, Expression, and One-Step Purification of the Minimal Essential Domain of the Light Chain of Botulinum Neurotoxin Type A Protein Expression and Purification ·Saloumeh Kadkhodayan, Mark S. Knapp, James J. Schmidt, Sarah E. Fabes, Bernhard Rupp, Rod Balhorn	2000	23
20	Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model Bioorganic & Medicinal Chemistry Letters ·Wooseok Han, Daniel Lopes De Menezes, Yongjin Xu, Mark S. Knapp, Robert A. Elling, Matthew T. Burger, Zhi‐Jie Ni, Aaron Smith	2016	22

About Mark S. Knapp

Mark S. Knapp is a scholar working on Molecular Biology, Genetics, Immunology, Organic Chemistry and Infectious Diseases, having authored 38 papers that have together received 3.0k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (10 papers), Quinazolinone synthesis and applications (5 papers), Biochemical and Molecular Research (4 papers), Chronic Lymphocytic Leukemia Research (4 papers), Protein Kinase Regulation and GTPase Signaling (3 papers), Cancer therapeutics and mechanisms (3 papers), Botulinum Toxin and Related Neurological Disorders (3 papers) and SARS-CoV-2 and COVID-19 Research (3 papers). The work is most often cited by research in Genetics (330 citations), Molecular Biology (1.8k citations), Hematology (236 citations), Physiology (92 citations) and Oncology (445 citations). Mark S. Knapp has collaborated with scholars based in United States, Switzerland and China. Frequent co-authors include Bernhard Rupp, Karl Heinrich Weisgraber, Mark L. Segall, Sissel Lund‐Katz, Michael C. Phillips, Julie A. Morrow, Pascal Furet, Joachim Blanz, Robin A. Fairhurst and Patricia Imbach‐Weese. Their work appears in journals such as ACS Medicinal Chemistry Letters, Bioorganic & Medicinal Chemistry Letters, Journal of Medicinal Chemistry, Biochemistry and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Mark S. Knapp

Impact in

Papers in i

In The Last Decade

Mark S. Knapp

Mark S. Knapp's Hit Papers

Peers

Countries citing papers authored by Mark S. Knapp

Fields of papers citing papers by Mark S. Knapp

All Works

About Mark S. Knapp

Explore authors with similar magnitude of impact

Papers in